Financial Data and Key Metrics Changes - For the third quarter of fiscal 2026, revenue increased by 10.2% to $4 million from $3.6 million in the prior year quarter [10] - Gross profit for the quarter totaled $3.2 million, up 17.6% from $2.8 million for the prior year period, with a gross profit percentage improvement to 81.5% from 76.4% [11] - EBITDA for the quarter was $280,000, corresponding to $0.01 on a per-share basis, marking the third consecutive quarter of positive EBITDA [15] Business Line Data and Key Metrics Changes - Recurring revenue reflects strong market adoption of the primary subscription model, with technology fees accounting for 91.2% of total revenue [9] - The digital health app user base grew from 4,500 to over 44,000 in two years, with an expanding network of over 2,500 providers supporting 400,000 patients annually [10] - Sales of BioCore Pro, the next-generation cardiac monitoring device, continued to expand, deepening penetration within current customers [6] Market Data and Key Metrics Changes - The demand for remote patient management solutions is accelerating due to the growing aging population and persistent resource shortages [3] - The company is focusing on the U.S. market expansion while opportunistically expanding internationally through distribution partnerships [5] Company Strategy and Development Direction - The company aims to lead the transition from reactive care to proactive management with clinically superior technology and scalable infrastructure [4] - Strategic initiatives include expanding geographic footprint and entering ancillary verticals that fit naturally with the core business [12] - The focus remains on innovation and development in remote monitoring solutions for chronic cardiac disease prevention and management [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth and a shift to profitability in 2026, driven by strong demand for their products [19] - The company is committed to advancing its business through the commercialization of its Biocore, Bioflux, and Biocare products [16] Other Important Information - Operating expenses for the third quarter were $2.8 million, a decrease from $2.93 million in the same period last year [12] - The company achieved positive free cash flows for the last six consecutive quarters, setting a path toward profitability [14] Q&A Session Summary - There were no questions during the Q&A session, and the conference concluded with management expressing excitement about the prospects for 2026 [18][20]